Indian Pharma Market (IPM)- Highlights of March 2014: 2 Indian Vs. MNCs: IPM grew at 5.5% versus -1.1% for MNCs Amongst the top 50 in MNCs MSD grew the highest at 13.5%, followed by Allergan at 9.6% & Merck at 9.5% DPCO V/s Non DPCO Market: The DPCO 2013 containing molecules market was at –13.9% whereas the non DPCO market grew by 6.8% resulting in an overall growth of 3.9% for March 2014 The DPCO 2013 portfolio for GSK degrew at 23.5% & Ranbaxy degrew by 24.2%, whereas Sun Pharma in its DPCO 2013 portfolio degrew at 10.0% From therapy perspective 10 therapies have outgrown the IPM growth & 2 therapies have double digit growths Respiratory Market grew at 8.8%, Gastrointestinal market grew at 3.8% whereas Anti-infectives degrew at -3.3% Anti-diabetic market grows at 15.8% & Cardiac at 6.7% in chronic business Derma market grew by 9.2%, Regional Dynamics: From regional perspective 15 regions have outgrown the IPM growth Odisha market grew the highest at 15.1% followed by Jharkhand Market at 10.4% Molecules: The biggest molecule Amoxycillin + Clavulanic degrew by 2.7%, whereas Cefixime degrew at 9.1%. The markets of Glimepiride + Metformin grew at 33.9%, Vitamin - D grew by 26.4%, Levetiracetam by 23.7%, Rosuvastain by 22.7%, Telmisartan by 17.6% & Levocetirizine + Montelukast by 16.9%. Brands: Glycomet-GP grows at 26.3% amongst the top 10 Brands Amongst the top brands in the IPM, Lantus grew by 30%, Telma by 16.6%, Skinlite by 13.7%, Aciloc by 15% , Dexorange 10% amongst top 25 Brands New Launches in IPM: Total 87 Brands launched in March 2014 Silodal D, Quinvaxem & Coerip are the top NIs for the month of March 2014 Source: AIOCD Pharmasofttech AWACS
Posted on: Mon, 14 Apr 2014 02:46:08 +0000
Trending Topics
Recently Viewed Topics
© 2015